Telix Pharmaceuticals and CellSight Technologies Conclude Collaboration and License Agreement for VisAcT ImmunoPET Technology

MELBOURNE (Australia) and SAN FRANCISCO (USA) – 19 September 2017. Telix announces collaboration and licensing agreement with CellSight Technologies, Inc. for the VisAcT immunoPET imaging technology.

Telix is pleased to announce the conclusion of collaboration and licensing agreement with CellSight Technologies, Inc. (CellSight) for the VisAcT immunoPET imaging technology (VisAcT).

The VisAcT technology enables visualization of the localization and migration of immune cells using Positron Emission Tomography (PET), an important imaging modality in the management of cancer.

The agreement between the companies enables Telix to use the VisAcT imaging technology in the development of its portfolio of molecularly-targeted radiation (MTR) therapeutics. There is a significant immune response component to the therapeutic use of targeted radiation and Telix believes that the VisAcT technology will assist in understanding the optimal dosing and delivery of MTR therapeutics, including in combination with checkpoint inhibitors.

Telix CEO Christian Behrenbruch stated, “We are very pleased to be working with Aruna and the CellSight team, and to be able to deploy this technology in our planned clinical trials. The imaging of immune function with PET has the potential to greatly enhance the optimization of our therapeutic products and CellSight and their collaborators at UCSF and Stanford are thought leaders in this field.”

CellSight CEO Aruna Gambhir stated, “Telix joins a number of international biopharmaceutical companies that have recognized the potential of CellSight’s VisAcT technology in visualizing immune response. We are delighted to be working with the Telix team, to support the use of our technology for their internal development programs. We will also be working closely with the Telix team for the manufacturing and clinical provision of VisAcT technology in Australia and New Zealand, where there is considerable interest in the use of the technology to support cancer immunology clinical trials, particularly for melanoma.”

To read the full press release click here.